<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Cardiovascular Disease & Underlying Inflammatory Events

Posted by MD Biosciences on May 10, 2011 2:51:00 PM

Cardiovascular disease (CVD) including heart disease, vascular disease and atherosclerosis are the most critical global health threats.

An estimated 26 million people are living with the effects of heart disease and is a major cause of death in western society. Until recently the widely held belief was that the CVD is simply the process as a build up of fat on the surface of artery walls. Eventually, this build up of fat blocks the artery and a heart attack or stroke occurs. However, the process has now been identified as a disease of the inner artery wall (intima) and inflammation is a key factor in its progression.

Read More

Topics: Inflammation, Cardiovascular

Inflammation & Pain Processing: Customizable Preclinical Models

Posted by MD Biosciences on May 4, 2011 1:46:00 PM


Chronic, destructive inflammation is at the core of a wide variety of diseases and conditions.

Inflammation, whether acute or chronic, is very often associated with pain. Similar to inflammation, pain can be physiological (an adaptive means of protecting tissues from real or perceived danger) or pathological (chronic, and often debilitating despite resolution of the original stimulus). Chronic pain can be caused by a variety of situations including inflammatory diseases such as osteo‐ and rheumatoid arthritis (inflammatory pain), tumor formation (cancer pain), and nerve injury (neuropathic pain).

Read More

Topics: Pain, Inflammation

Link Between TH17 & Osteoclast Function in RA

Posted by MD Biosciences on Apr 19, 2011 11:33:00 AM

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects approximately 1% of the population, and in 2010 cost the US alone $39.2 billion (1,2).  The disease is characterized by bone erosion, cartilage damage, synovial hyperplasia and cellular infiltration, all of which result in debilitating joint pain and stiffness (1,3,4).  Studying preclinical models such as the collagen-induced arthritis (CIA) model and the anti-collagen antibody induced arthritis (ACAIA) model, which show the above hallmarks of disease has allowed the identification of the cells and cytokines involved in the pathogenesis of the disease (5,6).
Read More

Topics: Inflammation

Anti-inflammatory Cytokines | Potential Targets In Neuropathic Pain

Posted by MD Biosciences on Apr 15, 2011 9:29:00 AM

We are continuing our series on the immune system, inflammation related factors and potential drup targets that fall in the overlap of the immune and nervous system. Our last discussion covered the pro-inflammatory cytokines and their relevance to neuropathic pain. This week we will cover anti-inflammatory cytokines.

Read More

Topics: Pain, Inflammation

Adipose Tissue - A Site of Inflammation?

Posted by MD Biosciences on Apr 12, 2011 11:41:00 AM

Inflammatory events associated with Obesity

Read More

Topics: Inflammation

Suitable Preclinical Models Needed For Novel Asthma Treatments

Posted by MD Biosciences on Apr 6, 2011 11:08:00 AM

There is a major unmet need in the treatment of asthma which is growing in incidence and prevalence in industrialized countries. The prevalence of asthma has doubled in the Western world over the previous 20 years. In addition to the estimated 180,000 asthma related deaths per year, there is a substantial economic burden due to lost school/work days and increased medical costs.

Read More

Topics: Inflammation

Pro-inflammatory Cytokines | Potential Neuropathic Pain Targets

Posted by MD Biosciences on Apr 4, 2011 1:06:00 PM

Over the past few weeks we have been reviewing the overlap between the nervous and immune systems. We recently discussed the various cell types involved and are going to move into some of the various inflammation related drug targets that may have potential involvement in neuropathic pain. We'll start with pro-inflammatory cytokines.

Read More

Topics: Pain

T-cells in Rheumatoid Arthritis | Where, Why & When?

Posted by MD Biosciences on Mar 28, 2011 12:02:00 PM

The role of T-cells and their actions in rheumatoid arthritis (RA) has been the focus of a great deal of research for some time [1], mainly as a result of many observations in human patients and experimental animal models.  The association of Human Leukocyte Antigen (HLA) DR, a MHC class II cell surface receptor, in RA provides the strongest evidence that CD4+ T-cells are involved in the development of disease [2, 3, 6]. Many other types of T-cells, including CD8+, regulatory T-cells and γδ T-cells have been shown to play different roles in the progression of RA [1, 2, 3, 8]. The mechanisms of disease involved in RA are still unknown; however the main hypothesis theorizes that auto antigens are presented to auto reactive T helper cells, which then orchestrate the inflammatory processes which are characteristic of the disease [3]. The nature of the antigens involved is unknown however several candidates have been suggested, most recently, citrullinated proteins [5, 6].

Read More

Topics: Inflammation

Cells Involvement|Neuro/Immune Interactions Along Pain Processing Pathway

Posted by MD Biosciences on Mar 15, 2011 2:19:00 PM

Previously we discussed various interactions that occur between the immune and nervous systems that are potential contributors to neuroinflammatory disorders. In this post, we will call out some of the specific cells involved in these interactions.

At the anatomical level, neuro‐immune interactions have been shown to take place all along the pain processing pathway. This is partially facilitated by increased permeability of the blood‐brain barrier following SCI or peripheral nerve injury [1]. At the cellular level, neuro‐immune interactions involve leukocytes including mast cells, neutrophils, macrophages, and T cells as well as glial cells with immunelike functions including Schwann cells and satellite glial cells in the PNS and microglia and astrocytes in the CNS. Alterations in glial cell function other than those associated with immune cells, immune system signaling molecules, or immune‐like functions of glial cells (i.e., alterations in neurotrophic factor signaling, potassium ion buffering, neurotransmitter re‐uptake, or gap junction maintenance) are outside the scope of this review and are not included here.

Read More

Topics: Pain, Inflammation

Case study: 25 Preclinical CAIA studies, 18 months, 1 Out-licensed Compound

Posted by MD Biosciences on Mar 7, 2011 2:14:00 PM

With the number of blockbuster drugs approaching patent expiration and pharma companies struggling to maintain pipeline and portfolios with in-house programs, companies are increasingly turning to licensing, aquisitions and partnerships. Early-stage licensing deals tend to carry more risk for pharma companies in-licensing. To offset this risk, additional data may be required from the pharma partner to confirm any internal research performed by the biotech/out-licensing company.

Mini-case study. MD Biosciences helps a medium-sized biotech company to develop Rheumatoid Arthritis drug for out-licensing in under two years.

Read More

Topics: CRO/outsourcing